Summary
Eluxadoline, a µ-opioid receptor agonist and d-opioid receptor antagonist, exhibits rapid onset of action along with sustained efficacy over the 6-month treatment period as studied in the phase 3, double-blind, placebo-controlled IBS3001 and IBS3002 trials in patients with diarrhea-predominant irritable bowel syndrome.
- eluxadoline
- irritable bowel syndrome with diarrhea
- IBD3001
- IBS3002
- µ-opioid receptor agonist
- d-opioid receptor antagonist
- irritable bowel syndrome
- gastroenterology clinical trials
- © 2015 SAGE Publications
Tools
Eluxadoline Shows Efficacy for IBS-D in IBS3001 and IBS3002 Phase 3 Trials
Permalink:
Table of contents
Cited By...
- No citing articles found.